sitagliptin accord
accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, type 2 - leki stosowane w cukrzycy - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.
metformax sr combi 100 mg + 1000 mg tabletki o zmodyfikowanym uwalnianiu
teva pharmaceuticals polska sp. z o.o. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 100 mg + 1000 mg
metformax sr combi 50 mg + 500 mg tabletki o zmodyfikowanym uwalnianiu
teva pharmaceuticals polska sp. z o.o. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 50 mg + 500 mg
metformax sr combi 50 mg + 1000 mg tabletki o zmodyfikowanym uwalnianiu
teva pharmaceuticals polska sp. z o.o. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 50 mg + 1000 mg
lonamo 100 mg tabletki powlekane
egis pharmaceuticals plc - sitagliptin hydrochloride monohydrate - tabletki powlekane - 100 mg
lonamo 50 mg tabletki powlekane
egis pharmaceuticals plc - sitagliptin hydrochloride monohydrate - tabletki powlekane - 50 mg
sitagliptin + metformin hydrochloride grindeks 50 mg + 850 mg tabletki powlekane
as grindeks - sitagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 850 mg
sitagliptin + metformin hydrochloride grindeks 50 mg + 1000 mg tabletki powlekane
as grindeks - sitagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 1000 mg
sitagliptin+metformin hcl medical valley 50 mg + 850 mg tabletki powlekane
medical valley invest ab - sitagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 850 mg
sitagliptin+metformin hcl medical valley 50 mg + 1000 mg tabletki powlekane
medical valley invest ab - sitagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 1000 mg